uploads/2016/10/Graph-1-5-1.png

Analysts’ Recommendations for Amgen and Its Peers in 2016

By

Updated

Analysts’ recommendations for Amgen

Based on the recommendations of 28 brokerage firms in a Bloomberg survey, 46.2% of the analysts gave Amgen (AMGN) a “buy” recommendation, while 53.8% of the analysts rated the company a “hold.” None of the analysts rated Amgen a “sell.”

In the first nine months of 2016, Amgen witnessed strong volume growth for its key products such as Xgeva, Prolia, Nplate, Vectibix, and Sensipar. The company also reported strong growth in volumes sold in international markets, despite intense competition. It highlights the inherently healthy demand existing for Amgen’s products across the world.

Amgen’s restructuring program also played a pivotal role in the company’s progress towards its long-term objectives. To learn more about the restructuring program, read Amgen Initiates Restructuring Plan.

The consensus 12-month target price for Amgen is ~$186.78—a rise of 28.7% from the stock’s last price of $145.18 on October 28, 2016.

If Amgen’s share price manages to reach this price target, it might boost the iShares Russell 1000 ETF (IWB). Amgen accounts for ~0.53% of IWB’s total portfolio.

Article continues below advertisement

Peer companies

Based on a Bloomberg survey of 30 broker firms, Celgene (CELG) received “buy” recommendations from 82.1% of the firms and “hold” recommendations from 14.3% of the firms. Only 3.6% of the firms rated Celgene as “sell.” The consensus 12-month target price for Celgene is ~$138.87—a rise of 33.7% from the stock’s last price of $103.9 on October 28, 2016.

Among the 27 brokerage firms surveyed by Bloomberg for Regeneron (REGN), 46.2% gave it a “buy” recommendation, while 50.0% gave it a “hold” recommendation. Only 3.8% of the firms rated Regeneron as “sell.” The consensus 12-month target price for Regeneron is ~$464.9—a rise of 30.7% from the stock’s last price of $355.83 on October 28, 2016.

Based on a Bloomberg survey of 30 broker firms, Gilead Sciences (GILD) received “buy” recommendations from 57.1% of the firms and “hold” recommendations from 42.9% of the firms. The consensus 12-month target price for Gilead Sciences is ~$101.38—a rise of 37.2% from the stock’s closing price of $73.88 on October 28, 2016.

In the next part, we’ll explore the growth trends for Amgen in 2016.

Advertisement

More From Market Realist